Patent · US Active

Priming of cancer cells with low dose naltrexone

US11065245B2 · kind B2 · utility

0Cited by

1References

13Claims

0Family size

Assignee

Cancer Vaccine Institute · GB

Inventors

Angus Dalgleish · London, GB
Wai Liu · London, GB

Key dates

Filing date	Jun 9, 2015
Grant date	Jul 20, 2021
Priority date	—
Expiry date	Sep 9, 2035

Classification

Technology area (CPC G)Physics
CPC primaryG01N2510/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The disclosure provides methods of treating a tumor/cancer by administering naltrexone or an analogue thereof, followed by a recovery phase, and then administering a small molecule signaling inhibitor such as PI3-kinase inhibitors, AKT inhibitors, taxanes, antimetabolites, alkylating agents and/or cell cycle inhibitors. The disclosure also provides diagnostic methods for assessing a therapeutic response to the methods of treatment.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.